- Home
- NVT vs ONC Comparison
NVT vs ONC Comparison
Compare NVT & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVT | ONC |
|---|---|---|
| Founded | 1903 | 2010 |
| Country | United Kingdom | Switzerland |
| Employees | N/A | 12000 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6B | 31.4B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | NVT | ONC |
|---|---|---|
| Price | $169.31 | $285.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | $131.36 | ★ $385.10 |
| AVG Volume (30 Days) | ★ 2.0M | 286.3K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.61% | N/A |
| EPS Growth | ★ 118.78 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $3,893,100,000.00 | N/A |
| Revenue This Year | $19.44 | $723.76 |
| Revenue Next Year | $12.41 | $15.04 |
| P/E Ratio | ★ $194.85 | $614.06 |
| Revenue Growth | ★ 29.51 | N/A |
| 52 Week Low | $69.04 | $240.00 |
| 52 Week High | $184.64 | $385.22 |
Technical Indicators
Market Signals| Indicator | NVT | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 52.40 | 54.57 |
| Support Level | $152.61 | $271.47 |
| Resistance Level | $179.21 | $310.50 |
| Average True Range (ATR) | 6.65 | 7.60 |
| MACD | -1.01 | 3.37 |
| Stochastic Oscillator | 52.01 | 83.66 |
Price Performance
Historical ComparisonAbout NVT nVent Electric plc
NVent is a leading global provider of electrical connection and protection solutions that touch a broad range of end markets, including infrastructure, industrial, commercial, and residential. NVent designs, manufactures, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.
About ONC BeiGene Ltd. American Depositary Shares
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.